MCAM and breast cancer: In breast cancer patients, the β1/CD29 integrin increases radiation resistance and forms a new co-receptor complex with CD146, a distinct inducer of the epithelial-to-mesenchymal transition (EMT) that is especially strongly expressed in triple-negative breast cancer (TNBC) [35].